National Cancer Institute (NCI) clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
85 trials changed in the last 30 days: 1 stopped, 27 with notable changes, 57 with minor changes only.
- Minor: Immunotherapy After Surgery · No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Trial sites expanded: 284 → 287 locations
- Minor: Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Trial sites expanded: 148 → 171 locations
- Minor: Different Treatment Lengths for Venetoclax · Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Trial sites expanded: 69 → 83 locations
- Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable: Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Start date pushed from Nov 23, 2026 to Jan 19, 2027
- Minor: Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Enrollment closed, study ongoing
- Notable: Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study Enrollment increased: 1 → 946 participants
- Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 258 → 262 locations
- Minor: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer · a Weakened Immune System Trial sites expanded: 57 → 60 locations
- Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 22 → 27 locations
- Minor: Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial Trial sites expanded: 11 → 14 locations
- Minor: Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Trial sites expanded: 149 → 152 locations
- Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations
- Minor: Methoxyamine, Cisplatin, and Pemetrexed Disodium · Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Study completion pushed from Oct 15, 2026 to Oct 15, 2027
- Notable: Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Results posted: Nov 17, 2026
- Notable: Biological Effects of DS-8201a on · Advanced Cancer Results posted: Nov 17, 2026
- Notable: Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Recruitment opened
- Notable: 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations Eligibility criteria changed
- Minor: Chemoradiotherapy With or Without Atezolizumab · Localized Muscle Invasive Bladder Cancer Primary completion date changed from estimate of Jun 1, 2027 to Jul 23, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07937696 A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch… | Phase 2 | Not Yet Recruiting |
| 2026-11-04 | NCT07914855 Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | Phase 2 | Not Yet Recruiting |
| 2026-10-29 | NCT07902921 STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-23 | NCT07891286 Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children… | Phase 2 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 162 | |
| Phase 1/2 | 78 | |
| Phase 2 | 317 | |
| Phase 2/3 | 17 | |
| Phase 3 | 79 | |
| Phase 4 | 3 |
Not charted: 124 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 50
Leukemia (95) · Lung Cancer (80) · Non-Hodgkin Lymphoma (69) · Sarcoma (67) · Breast Cancer (57) · Multiple Myeloma (52) · Colorectal Cancer (51) · Ovarian Cancer (49) · Non-Small Cell Lung Cancer (NSCLC) (47) · Head & Neck Cancer (46)
Get alerts when National Cancer Institute (NCI)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.